他汀类药物在慢性肝病和肝硬化患者中的应用现状及展望

Joshua George, Pavana Reddy, Stefy Jacob, M Sunitha, Vineeth Chandy
{"title":"他汀类药物在慢性肝病和肝硬化患者中的应用现状及展望","authors":"Joshua George, Pavana Reddy, Stefy Jacob, M Sunitha, Vineeth Chandy","doi":"10.18231/j.ijpp.2023.040","DOIUrl":null,"url":null,"abstract":"The objective of this study is to examine the existing evidence concerning the utilization of statins in individuals diagnosed with chronic liver disease and cirrhosis. Chronic liver diseases, such as cirrhosis and hepatocellular carcinoma, present substantial challenges to public health worldwide. The use of statins in these conditions has been a subject of concern due to potential liver injury risks. However, recent evidence from pre-clinical and clinical studies suggests that statins may have positive effects on disease progression, portal hypertension, and hepatocellular carcinoma prevention. These cholesterol-lowering drugs exhibit pleiotropic effects, including anti-inflammatory, anti-fibrotic, and antiangiogenic properties, which contribute to their potential benefits in chronic liver disease. While further research and randomized controlled trials are needed, statins offer a promising therapeutic avenue to prevent disease progression and improve outcomes in patients with chronic liver diseases. Despite the global burden of chronic liver diseases and the limited availability of effective medications, statins have emerged as potential agents to address these conditions. Their primary cholesterol-lowering effect is complemented by additional mechanisms that positively impact inflammation, fibrosis, endothelial function, thrombosis, and coagulation. Although concerns persist regarding their hepatotoxic risks, studies have demonstrated the potential of statins to reduce the risk of disease progression, hepatic decompensation, hepatocellular carcinoma development, and mortality. Nonetheless, further large-scale randomized controlled trials focusing on clinical endpoints are necessary to ascertain the efficacy and safety of statin treatment in chronic liver diseases. Overall, statins hold promise as a valuable addition to the treatment armamentarium for chronic liver diseases, warranting further investigation and consideration in clinical practice.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":"13 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Current views and prospects relating to the use of statins in patients with chronic liver disease and cirrhosis\",\"authors\":\"Joshua George, Pavana Reddy, Stefy Jacob, M Sunitha, Vineeth Chandy\",\"doi\":\"10.18231/j.ijpp.2023.040\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The objective of this study is to examine the existing evidence concerning the utilization of statins in individuals diagnosed with chronic liver disease and cirrhosis. Chronic liver diseases, such as cirrhosis and hepatocellular carcinoma, present substantial challenges to public health worldwide. The use of statins in these conditions has been a subject of concern due to potential liver injury risks. However, recent evidence from pre-clinical and clinical studies suggests that statins may have positive effects on disease progression, portal hypertension, and hepatocellular carcinoma prevention. These cholesterol-lowering drugs exhibit pleiotropic effects, including anti-inflammatory, anti-fibrotic, and antiangiogenic properties, which contribute to their potential benefits in chronic liver disease. While further research and randomized controlled trials are needed, statins offer a promising therapeutic avenue to prevent disease progression and improve outcomes in patients with chronic liver diseases. Despite the global burden of chronic liver diseases and the limited availability of effective medications, statins have emerged as potential agents to address these conditions. Their primary cholesterol-lowering effect is complemented by additional mechanisms that positively impact inflammation, fibrosis, endothelial function, thrombosis, and coagulation. Although concerns persist regarding their hepatotoxic risks, studies have demonstrated the potential of statins to reduce the risk of disease progression, hepatic decompensation, hepatocellular carcinoma development, and mortality. Nonetheless, further large-scale randomized controlled trials focusing on clinical endpoints are necessary to ascertain the efficacy and safety of statin treatment in chronic liver diseases. Overall, statins hold promise as a valuable addition to the treatment armamentarium for chronic liver diseases, warranting further investigation and consideration in clinical practice.\",\"PeriodicalId\":13313,\"journal\":{\"name\":\"Indian Journal of Pharmacy and Pharmacology\",\"volume\":\"13 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Pharmacy and Pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18231/j.ijpp.2023.040\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Pharmacy and Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18231/j.ijpp.2023.040","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本研究的目的是检查有关慢性肝病和肝硬化患者使用他汀类药物的现有证据。慢性肝病,如肝硬化和肝细胞癌,对全世界的公共卫生构成重大挑战。由于潜在的肝损伤风险,在这些情况下使用他汀类药物一直是一个值得关注的问题。然而,最近来自临床前和临床研究的证据表明,他汀类药物可能对疾病进展、门脉高压和肝细胞癌预防有积极作用。这些降胆固醇药物表现出多效性,包括抗炎、抗纤维化和抗血管生成特性,这有助于它们对慢性肝病的潜在益处。虽然需要进一步的研究和随机对照试验,但他汀类药物为预防慢性肝病患者的疾病进展和改善预后提供了一种有希望的治疗途径。尽管慢性肝病是全球负担,有效药物的可用性有限,但他汀类药物已成为解决这些疾病的潜在药物。它们的主要降胆固醇作用被其他积极影响炎症、纤维化、内皮功能、血栓形成和凝血的机制所补充。尽管对其肝毒性风险的担忧仍然存在,但研究已经证明他汀类药物具有降低疾病进展、肝失代偿、肝细胞癌发展和死亡率的潜力。然而,需要进一步的大规模随机对照试验来确定他汀类药物治疗慢性肝病的有效性和安全性。总的来说,他汀类药物有望成为治疗慢性肝病的有价值的补充,值得在临床实践中进一步研究和考虑。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Current views and prospects relating to the use of statins in patients with chronic liver disease and cirrhosis
The objective of this study is to examine the existing evidence concerning the utilization of statins in individuals diagnosed with chronic liver disease and cirrhosis. Chronic liver diseases, such as cirrhosis and hepatocellular carcinoma, present substantial challenges to public health worldwide. The use of statins in these conditions has been a subject of concern due to potential liver injury risks. However, recent evidence from pre-clinical and clinical studies suggests that statins may have positive effects on disease progression, portal hypertension, and hepatocellular carcinoma prevention. These cholesterol-lowering drugs exhibit pleiotropic effects, including anti-inflammatory, anti-fibrotic, and antiangiogenic properties, which contribute to their potential benefits in chronic liver disease. While further research and randomized controlled trials are needed, statins offer a promising therapeutic avenue to prevent disease progression and improve outcomes in patients with chronic liver diseases. Despite the global burden of chronic liver diseases and the limited availability of effective medications, statins have emerged as potential agents to address these conditions. Their primary cholesterol-lowering effect is complemented by additional mechanisms that positively impact inflammation, fibrosis, endothelial function, thrombosis, and coagulation. Although concerns persist regarding their hepatotoxic risks, studies have demonstrated the potential of statins to reduce the risk of disease progression, hepatic decompensation, hepatocellular carcinoma development, and mortality. Nonetheless, further large-scale randomized controlled trials focusing on clinical endpoints are necessary to ascertain the efficacy and safety of statin treatment in chronic liver diseases. Overall, statins hold promise as a valuable addition to the treatment armamentarium for chronic liver diseases, warranting further investigation and consideration in clinical practice.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信